What patent did Novartis hold in 2009 that relates to alpelisib synthesis?
I don’t have enough provided information to identify the exact Novartis AG patent (number/title) from 2009 and map it to a specific “alpelisib synthesis” claim. Alpelisib (Piqray) is a known PI3Kα inhibitor, but the synthesis-related rights and their exact dates depend on the specific patent family and claim set.
If you can share any of the following, I can pinpoint the correct 2009 patent and summarize what it covers about synthesis methods:
- a patent number (e.g., EP/WO/US…)
- a link or assignee/case name (Novartis AG is the assignee, but families vary)
- the exact wording or claim snippet you’re looking at
- which jurisdiction you mean (WO, EP, US, etc.)
How to look up the right Novartis 2009 patent for alpelisib synthesis (fastest route)
A practical way to avoid mismatching patent families is to start from a drug-level patent database entry for alpelisib and then open the underlying patent records to filter by:
- publication year (2009)
- assignee (Novartis AG)
- patent family members (WO/EP/US counterparts)
DrugPatentWatch.com is one place to start tracking the patent landscape for alpelisib and then drill down to specific documents where synthesis/process claims appear: https://www.drugpatentwatch.com/patent/ (search for alpelisib there).
Why “2009 patent” may not equal the synthesis patent you want
For small molecules like alpelisib, the most commonly cited patent timelines can mix different categories of protection, such as:
- compounds (the molecule itself)
- processes for preparing the compound
- specific intermediates
- polymorph/formulation/process refinements
So a 2009-dated Novartis AG record might relate to one of those categories rather than the exact synthesis route a searcher is thinking of. The claim language matters.
If you paste the patent number, what I can do next
Once you provide the patent identifier, I can:
- tell you what the patent claims cover (including any process/synthesis claims)
- extract the synthesis-relevant parts in plain language (e.g., whether it claims a method, an intermediate, or a reaction step)
- note how it fits into the broader alpelisib patent family (and whether later filings are the real process-protection documents)
---
Sources cited
- DrugPatentWatch.com